Le Lézard
Classified in: Health
Subject: PLW

H-Source Announces U.S. Patent


VANCOUVER, July 18, 2018 /CNW/ - H-Source Holdings Ltd. (TSX VENTURE:HSI)(OTCQB:HSCHF) (the "Company" or "H-Source") is pleased to announce that it has received allowance by the U.S Patent and Trademark Office (USPTO) for U.S. Patent Application No. 12/772,019.

"We are pleased the USPTO has allowed our patent, Perishable medical product management systems, perishable medical product management methods, and perishable medical product resale methods. Intellectual property (IP) has been a focus for us from the beginning. Combined with our granted patent in Japan and additional pending applications, we are committed to growing our IP portfolio. Our current allowed and granted patents not only support our existing platform but will also provide us new opportunities to innovate and offer breakthrough healthcare solutions," said Murray Walden, President of H-Source.

About H-Source Holdings Ltd.

H-Source Holdings Ltd. is a technology company operating within the healthcare industry through its wholly owned subsidiary, H-Source, Inc. The Company has developed a transaction platform that provides a private, secure and trusted marketplace for healthcare members to buy, sell and transfer devices, pharmaceuticals, capital equipment and supplies with each other. Members can conduct secure transactions within Integrated Delivery Networks, complete H-Source marketplace or customize their own group hospitals using H-Source's built-in filters. This private marketplace platform is specifically designed to reduce health care costs and medical product waste. For more information, please visit http://h-source.com/.

On behalf of the board of directors of H-Source Holdings Ltd.

"John Kupice"        
John Kupice
CEO & Director

CAUTIONARY DISCLAIMER STATEMENT: The TSXV has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company's shares on the TSXV and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the TSXV and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE H-Source Holdings Ltd.


These press releases may also interest you

at 07:35
Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, today announced positive, primary results up to Day 91 for its Phase II exploratory STARGAZE trial evaluating apraglutide in patients with steroid-refractory gastrointestinal acute...

at 07:35
dentalcorp Holdings Ltd. ("dentalcorp" or the "Company") , Canada's largest and one of North America's fastest growing networks of dental practices, today announced that it will present at the following investor conferences: 2024 Bloom Burton & Co....

at 07:30
Optimi Health Corp. (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly...

at 07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of...

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024...

at 07:30
Ophthalmic lens technology leader HOYA Vision Care announced the launch of iD LifeStyle® 4 with 3D Binocular Visiontm technology, the newest progressive lens in its award-winning iD LifeStyle® family, now available to order across Canada. Building...



News published on and distributed by: